je.st
news
Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done
2013-06-14 22:19:31| Biotech - Topix.net
One day later, Wall Street analysts are reacting accordingly. Sell side does an abrupt about face on $MYGN - after glowing reviews yesterday - both ML and RBC downgrade - CSFB very negative comments - Ian Estepan June 14, 2013 CSFB: we see competitors will offer the test for $995 if they do not lower price payors will shift - Ian Estepan June 14, ... (more)
Tags: street
risk
wall
tests
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||